Repeated intraportal injection of mesenchymal stem cells in combination with pioglitazone in patients with compensated cirrhosis: A clinical report of two cases

Archives of Iranian Medicine

Volumn 19, Issue 2, 2016, Pages 131-136

  Vosough, Massoud ^a   Moossavi, Shirin ^b,c   Mardpour, Soura ^a   Akhlaghpoor, Shahram ^d   Azimian, Vajiheh ^a   Jarughi, Neda ^a   Hosseini, Seyedeh Esmat ^a   Ashrafi, Mandana ^b,c   Nikfam, Sepideh ^b,c   Aghdami, Nasser ^a   Malekzadeh, Reza ^b,c   Mohamadnejad, Mehdi ^b,c   Baharvand, Hossein ^a  

^a ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Noor Medical Imaging Center   (Iran)

Author keywords

Cell therapy; Cirrhosis; Mesenchymal stem cell; Pioglitazone; PPAR y

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CREATININE; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ACUTE KIDNEY FAILURE; ADULT; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; ASCITES; CASE REPORT; COMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; INTERNATIONAL NORMALIZED RATIO; LIVER FUNCTION TEST; MALE; MESENCHYMAL STEM CELL; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; PORTAL HYPERTENSION; PROTHROMBIN TIME; STEM CELL TRANSPLANTATION; AGONISTS; HEPATIC PORTAL VEIN; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRRHOSIS; MESENCHYMAL STEM CELL TRANSPLANTATION; PATHOPHYSIOLOGY; PILOT STUDY; PROCEDURES;

ADULT; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; LIVER CIRRHOSIS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; PILOT PROJECTS; PORTAL VEIN; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 84957599728     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest. 2013; 123(5): 1887-1901.
2. Ramachandran R, Iredale JR Liver fibrosis: a bidirectional model of fibrogenesis and resolution. gJM. 2012; 105(9): 813-817.
3. Wells RG, Schwabe RE Origin and function of myofibroblasts in the liver. Semin LiverDis. 2015; 35(2): 97-106.
4. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011; 25(2): 195-206.
5. Pfutzner A, Weber MM, Forst T. Pioglitazone: update on an oral antidia-betic drug with antiatherosclerotic effects. Expert Opin Pharmacother. 2007; 8(12): 1985-1998.
6. Jones JR, Barrick C, Kim KA, Lindner J, Blondeau B, Fujimoto Y, et al. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc Natl Acad Sci US A. 2005; 102(17): 6207-6212.
7. Wei J, Bhattacharyya S, Jain M, Varga J. Regulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-gamma: A Novel Link Between Metabolism and Fibrogenesis. OpenRheumatolJ. 2012; 6: 103-115.
8. Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF, Jr., Motomura K, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem. 2000; 275(46): 35715-35722.
9. Yang L, Chan CC, Kwon OS, Liu S, McGhee J, Stimpson SA, et al. Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am JPhysiol Gastrointest Liver Physiol. 2006; 291(5): G902-G911.
10. Wang Z, Xu JP, Zheng YC, Chen W, Sun YW, Wu ZY, et al. Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats. Hepatobiliary PancreatDis Int. 2011; 10(1): 64-71.
11. Uto H, Nakanishi C, Ido A, Hasuike S, Kusumoto K, Abe H, et al. The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, 1-amino acid-defined diet. Hepatol Res. 2005; 32(4): 235-242.
12. Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defineddiet. Biochem Biophys Res Commun. 2004; 315(1): 187-195.
13. Schwabl P, Payer BA, Grahovac J, Klein S, Horvatits T, Mitterhauser M, et al. Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. J Hepatol. 2014; 60(6): 1135-1142.
14. Aghaei I, Shabani M, Doustar N, Nazeri M, Dehpour A. Peroxisome proliferator-activated receptor-gamma activation attenuates motor and cognition impairments induced by bile duct ligation in a rat model of hepatic cirrhosis. Pharmacol Biochem Behav. 2014; 120: 133-139.
15. Hajiaghamohammadi AA, Ziaee A, Oveisi S, Masroor H. Effects of metfor-min, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study. Hepat Mon. 2012; 12(8): e6099.
16. Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA, et al. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology. 2012; 56(4): 1311-1318.
17. Gastaldelli A, Harrison S, Belfort-Aguiar R, Hardies J, Balas B, Schen-ker S, et al. Pioglitazone in the treatment of NASH: the role of adiponec-tin. Aliment Pharmacol Ther. 2010; 32(6): 769-775.
18. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010; 52(1): 79-104.
19. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steato-hepatitis. NEngl J Med. 2010; 362(18): 1675-1685.
20. Gastaldelli A, Harrison SA, Befort-Aguilar R, Hardies LJ, Balas B, Schen-ker S, et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology. 2009; 50(4): 1087-1093.
21. Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials. 2009; 30(1): 88-96.
22. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008; 135(4): 1176-1184.
23. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology. 2007; 46(2): 424-429.
24. Lutchman G, Promrat K, Kleiner DE, Heller T, Ghany MG, Yanovski JA, et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol. 2006; 4(8): 1048-1052.
25. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004; 39(1): 188-196.
26. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355(22): 2297-2307.
27. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004; 2(12): 1107-1115.
28. Vosough M, Moslem M, Pournasr B, Baharvand H. Cell-based therapeutics for liver disorders. Br Med Bull. 2011; 100: 157-172.
29. Lorenzini S, Andreone P. Stem cell therapy for human liver cirrhosis: a cautious analysis of the results. Stem Cells. 2007; 25(9): 2383-2384.
30. Gilchrist ES, Plevris JN. Bone marrow-derived stem cells in liver repair: 10 years down the line. Liver Transpl. 2010; 16(2): 118-129.
31. Pai M, Spalding D, Xi F, Habib N. Autologous bone marrow stem cells in the treatment of chronic liver disease. Int J Hepatol. 2012;it does not have it: 307165.
32. Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, Bagheri M, Bashtar M, Ghanaati H, et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med. 2007; 10(4): 459-466.
33. Kharaziha P, Hellstrom PM, Noorinayer B, Farzaneh F, Aghajani K, Ja-fari F, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol. 2009; 21(10): 1199-1205.
34. Peng L, Xie DY, Lin BL, Liu J, Zhu HP, Xie C, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology. 2011; 54(3): 820-828.
35. Zhao W, Li JJ, Cao DY, Li X, Zhang LY, He Y, et al. Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis. World J Gastroenterol. 2012; 18(10): 1048-1058.
36. Abdel Aziz MT, Atta HM, Mahfouz S, Fouad HH, Roshdy NK, Ahmed HH, et al. Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis. Clin Biochem. 2007; 40(12): 893-899.
37. Motawi TM, Atta HM, Sadik NA, Azzam M. The therapeutic effects of bone marrow-derived mesenchymal stem cells and simvastatin in a rat model ofliverfibrosis. Cell Biochem Biophys. 2014; 68(1): 111-125.
38. Rabani V, Shahsavani M, Gharavi M, Piryaei A, Azhdari Z, Baharvand H. Mesenchymal stem cell infusion therapy in a carbon tetrachloride-in-duced liver fibrosis model affects matrix metalloproteinase expression. Cell Biol Int. 2010; 34(6): 601-605.
39. Lee SR, Lee SH, Moon JY, Park JY, Lee D, Lim SJ, et al. Repeated administration of bone marrow-derived mesenchymal stem cells improved the protective effects on a remnant kidney model. Ren Fail. 2010; 32(7): 840-848.
40. Chang DY, Yoo SW, Hong Y, Kim S, Kim SJ, Yoon SH, et al. The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase. Int J Cancer. 2010; 127: 1975-1983.
41. Ho JH, Tseng TC, Ma WH, Ong WK, Chen YF, Chen MH, et al. Intravenous transplantations of mesenchymal stem cells effectively restore long-term blood glucose homeostasis by hepatic engraftment and beta cell differentiation in streptozosin-induced diabetic mice. Cell Transplant. 2012; 21(5): 997-1009.
42. Rajvanshi R Kerr A, Bhargava KK, Burk RD, Gupta S. Efficacy and safety of repeated hepatocyte transplantation for significant liver repop-ulation in rodents. Gastroenterology. 1996; 111(4): 1092-1102.
43. Sauer V, Siaj R, Stoppeler S, Bahde R, Spiegel HU, Kohler G, et al. Repeated transplantation of hepatocytes prevents fulminant hepatitis in a rat model of Wilson's disease. Liver Transpl. 2012; 18(2): 248-259.
44. Yannaki E, Anagnostopoulos A, Kapetanos D, Xagorari A, Iordanidis F, Batsis I, et al. Lasting amelioration in the clinical course of decompen-sated alcoholic cirrhosis with boost infusions of mobilized peripheral blood stem cells. ExpHematol. 2006; 34(11): 1583-1587.
45. Miryounesi M, Piryaei A, Pournasr B, Aghdami N, Baharvand H. Repeated versus single transplantation of mesenchymal stem cells in carbon tetrachloride-induced liver injury in mice. Cell Biol Int. 2013; 37(4): 340-347.
46. Mohamadnejad M, Sohail MA, Swenson ES, Popov Y, Sverdlov DY, Sharma A. Bone marrow-derived mesenchymal stem cell transplantation to enhance the anti-fibrotic effect of pioglitazone in hepatic fibrosis. Hepatology. 2009; 50: 811A.
47. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22(6): 696-699.
48. Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroen-terol. 2011; 4(6): 391-417.
49. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol. 2000; 28(8): 875-884.
50. Hou R, Liu R, Niu X, Chang W, Yan X, Wang C, et al. Biological characteristics and gene expression pattern of bone marrow mesenchymal stem cells in patients with psoriasis. Exp Dermatol. 2014; 23(7): 521-523.
51. Mohamadnejad M, Alimoghaddam K, Bagheri M, Ashrafi M, Abdol-lahzadeh L, Akhlaghpoor S, et al. Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis. Liver Int. 2013; 33(10): 1490-1496.
52. Li J, Zhang L, Xin J, Jiang L, Li J, Zhang T, et al. Immediate intraportal transplantation of human bone marrow mesenchymal stem cells prevents death from fulminant hepatic failure in pigs. Hepatology. 2012; 56(3): 1044-1052.
53. Voican CS, Perlemuter G. Insulin resistance and oxidative stress: two therapeutic targets in non-alcoholic steatohepatitis. J Hepatol. 2011; 54(2): 388-391.